Compare NICE Ltd (NICE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NICE Ltd vs Novo Nordisk A/S — how do they compare? NICE Ltd trades at $94.34 (market cap $5.91B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 37.3× NICE Ltd's market cap, and Novo Nordisk A/S pays a 3.63% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| NICE | NVO | |
|---|---|---|
Market Cap | $5.91B | $220.53B |
Sector | Technology | Health |
52-Week High | $170.37 | $71.70 |
52-Week Low | $83.15 | $35.29 |
Enterprise Value | $5.69B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
